Tr1x
Overview
Tr1X, Inc. (pronounced as "Trix") is a San Diego-based biotechnology company that focuses on developing allogeneic engineered regulatory T cell (Treg) and CAR-Treg cell therapies for autoimmune and inflammatory diseases. Founded by industry pioneers, including the scientists who discovered Tr1 cells, the company was founded in 2018 and has raised $75 million in its Series A funding round. Key investors include The Column Group, NEVA SGR, and Alexandria Venture Investments.
Recent Developments
- September 2024: Tr1X announced its participation in key healthcare investment conferences, such as the Goldman Sachs life sciences symposium, highlighting its growing influence in the life sciences field.
- August 2024: Tr1X received FDA clearance for its IND application on TRX103 for treatment-refractory Crohn's Disease, which aims at enrolling patients for a phase 1/2a study by the year's end.
- July 2024: The company successfully dosed the first patient in a trial with TRX103 for Graft versus Host Disease (GvHD) with no adverse effects and is anticipated to announce more data in late 2024.
- January 2024: Tr1X emerged from stealth mode, announcing a robust $75 million Series A financing, spearheaded by The Column Group, to engineer T-cell therapies targeting major autoimmune diseases.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2018 |
| Headquarters | San Diego, California, USA |
| Founders | Maria Grazia Roncarolo, David de Vries, Jan deVries, Jonathan Perrin |
| Revenue | N/A |
| Profits | N/A |
| Key Investors | The Column Group, NEVA SGR, Alexandria Venture Investments |
| Industry | Biotechnology Research |
| Number of Employees | 35 |
Early History
Tr1X was founded to address unmet medical needs in the field of autoimmune diseases by leveraging breakthrough cell therapy technologies. With foundational work led by Dr. Maria Grazia Roncarolo, a renowned figure in cell therapy and immunology, the company aimed to utilize discoveries around Tr1 cells to offer new therapeutic avenues. As the scientific understanding and applications of regulatory T cells advanced, Tr1X concentrated efforts on producing interventions that utilize these cells' powerful properties to treat and potentially cure chronic autoimmune conditions.
Company Profile and Achievements
Tr1X focuses on creating regulatory T cell therapies that are designed to modify the immune response to restore homeostasis and potentially cure diseases. Among its key achievements:
- Development of TRX103: Aimed at treating severe autoimmune diseases like GvHD and Crohn's Disease. The therapy was designed to be an off-the-shelf solution, anticipated to be free from severe side effects which are common in competing cell therapies.
- Series A Funding Completion: The substantial $75 million fund reflects investor confidence and positions Tr1X to expedite its pipeline development significantly.
- FDA Clearances: FDA clearances for investigative new drug applications, which allow for the clinical trials necessary to bring therapies to patients.
Current Operations and Market Position
Tr1X operates within the biotechnology research industry, primarily in developing cell-based therapies for immune modulation. It holds a reputable position for its advancements leveraging Tr1 cells for resolving immune-mediated diseases, being one of the few companies with a dedicated focus on Treg cell therapies. Tr1X's approach stands out due to its commitment to scalable, off-the-shelf products that can potentially reduce treatment costs and extend repeatable therapeutic dosing.
Related Topics
Tr1X Series A
Tr1X raised $75 million in January 2024 with the assistance of The Column Group and other investors, marking a financial leap intended to stimulate the advancement of Tr1 cell-based therapies.
TR1X GitHub
While primarily focused on biomedical innovations, Tr1X has publicly shared some resources and project repositories that align with digital healthcare integration.
Conclusion
Tr1X continues to demonstrate significant potential in the biotechnology industry, driven by the scientific leadership of its founders and a strategic focus on cell therapy innovation. Positioned in La Jolla, California, the company stands at the cutting-edge of immunotherapy research, with its pioneering approaches promising to open new therapeutic horizons for treatment-resistant diseases. With continuing advancements and successful clinical trials, Tr1X is poised to make a lasting impact on the landscape of autoimmune disease therapies.